• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone).

作者信息

Castriota-Scanderbeg A, Sacco M

机构信息

Department of Radiology, Scientific Institute S. Lucia, Roma, Italy.

出版信息

Br J Haematol. 1997 Feb;96(2):254-5. doi: 10.1046/j.1365-2141.1997.d01-2014.x.

DOI:10.1046/j.1365-2141.1997.d01-2014.x
PMID:9029008
Abstract

A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment. Changes in the humoral and cell-mediated immune function. including antinuclear antibodies (ANA), anti-DNA and extractable-nuclear antigens (ENA) antibodies positivity, increased immunoglobulin values, decreased T suppressor and the presence of circulating immune complexes, suggest a cause-and-effect relationship with the observed clinical manifestations. A careful monitoring of the immune function is recommended in patients who are receiving the oral iron chelator L1.

摘要

相似文献

1
Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone).
Br J Haematol. 1997 Feb;96(2):254-5. doi: 10.1046/j.1365-2141.1997.d01-2014.x.
2
Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.长期去铁酮(L1)治疗的结果:口服铁螯合剂国际研究小组的报告
Br J Haematol. 1995 Sep;91(1):224-9. doi: 10.1111/j.1365-2141.1995.tb05274.x.
3
A multi-center safety trial of the oral iron chelator deferiprone.口服铁螯合剂去铁酮的多中心安全性试验。
Ann N Y Acad Sci. 1998 Jun 30;850:223-6. doi: 10.1111/j.1749-6632.1998.tb10478.x.
4
Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature.一名地中海贫血患者的去铁酮相关性膝关节病:病例报告及文献复习
Clin Rheumatol. 2008 Nov;27(11):1459-61. doi: 10.1007/s10067-008-0969-y. Epub 2008 Jul 29.
5
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.口服铁螯合剂去铁酮长期治疗的安全性和有效性。
Blood. 2003 Sep 1;102(5):1583-7. doi: 10.1182/blood-2002-10-3280. Epub 2003 May 22.
6
Safety profile of the oral iron chelator deferiprone: a multicentre study.口服铁螯合剂去铁酮的安全性概况:一项多中心研究。
Br J Haematol. 2000 Feb;108(2):305-12. doi: 10.1046/j.1365-2141.2000.01866.x.
7
Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one.一名重型地中海贫血患者在接受口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮治疗期间发生粒细胞缺乏症。
Acta Haematol. 1993;89(2):86-90. doi: 10.1159/000204494.
8
Deferiprone: new preparation. Poorly assessed.去铁酮:新制剂。评估不足。
Prescrire Int. 2000 Oct;9(49):131-5.
9
Deferiprone-associated myelotoxicity.去铁酮相关的骨髓毒性。
Eur J Haematol. 1994 Nov;53(5):298-301. doi: 10.1111/j.1600-0609.1994.tb01323.x.
10
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.一项使用心血管磁共振评估去铁胺与去铁酮联合治疗对重型地中海贫血患者心肌铁影响的随机、安慰剂对照、双盲试验。
Circulation. 2007 Apr 10;115(14):1876-84. doi: 10.1161/CIRCULATIONAHA.106.648790. Epub 2007 Mar 19.

引用本文的文献

1
Agranulocyosis in Beta Thalassemia Major Patients treated with Oral Iron Chelating Agent (Deferiprone).接受口服铁螯合剂(去铁酮)治疗的重型β地中海贫血患者的粒细胞缺乏症
Oman Med J. 2008 Oct;23(4):275-7.
2
Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier.一名乙型肝炎表面抗原地中海贫血携带者在去铁酮和去铁胺联合治疗期间发生乙型肝炎病毒再激活。
Int J Hematol. 2009 Mar;89(2):135-138. doi: 10.1007/s12185-008-0229-6. Epub 2008 Dec 25.
3
Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature.
一名地中海贫血患者的去铁酮相关性膝关节病:病例报告及文献复习
Clin Rheumatol. 2008 Nov;27(11):1459-61. doi: 10.1007/s10067-008-0969-y. Epub 2008 Jul 29.
4
Deferiprone, efficacy and safety.
Indian J Pediatr. 2004 Mar;71(3):213-6. doi: 10.1007/BF02724272.
5
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.去铁酮治疗地中海贫血及其他病症铁过载的获益与风险:与去铁胺的流行病学及治疗学方面比较
Drug Saf. 2003;26(8):553-84. doi: 10.2165/00002018-200326080-00003.
6
Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.去铁酮:对其在重型β地中海贫血及其他依赖输血疾病的铁过载中临床潜力的综述
Drugs. 1999 Sep;58(3):553-78. doi: 10.2165/00003495-199958030-00021.